WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
The Absorb GT1 bioresorbable vascular scaffold (BVS, Abbott Vascular) will no longer be widely available in Europe as of May 31, 2017, with the company restricting use of the device to centers ...
Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...
Abbott Laboratories, one of the biggest makers of coronary stents in the world, is halting global sales of a fully absorbable stent that was once hailed as the next big breakthrough in medical devices ...
CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software Inc., a leading provider of cloud-based learning and performance management software for corporations and higher education institutions, announced ...
CALGARY, Alberta, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absorb Software, the leading global AI-driven learning platform provider, announced the launch of mentoring in Absorb LMS, a next-generation ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio At 2 years after implantation, a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results